Tevogen Bio Holdings Inc. (NASDAQ:TVGNW – Get Free Report) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totaling 155,699 shares, a growth of 80.5% from the September 15th total of 86,259 shares. Based on an average trading volume of 401,756 shares, the short-interest ratio is presently 0.4 days.
Tevogen Bio Stock Performance
NASDAQ TVGNW traded down $0.00 during trading hours on Friday, hitting $0.07. 113,481 shares of the company’s stock traded hands, compared to its average volume of 220,633. The business’s fifty day moving average price is $0.06 and its two-hundred day moving average price is $0.05. Tevogen Bio has a 52 week low of $0.03 and a 52 week high of $0.08.
About Tevogen Bio
Tevogen Bio is a clinical-stage biotechnology company focused on developing precision T-cell therapies for patients with viral infections and other immune-related diseases. The company’s platform is designed to produce targeted, off-the-shelf therapies using virus-specific cytotoxic T lymphocytes, with the aim of providing treatment without the need to collect and modify each patient’s own cells.
Tevogen’s lead product candidate, TVGN 489, is an investigational allogeneic T-cell therapy intended to target SARS-CoV-2-infected cells.
Further Reading
- Five stocks we like better than Tevogen Bio
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
